Century Therapeutics, Inc. (IPSC) company profile

Century Therapeutics is a biotechnology company that develops allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells. The company focuses on treatments for autoimmune diseases, type 1 diabetes, and cancers. Its primary pipeline candidates include CNTY-813, an engineered beta islet cell replacement therapy for type 1 diabetes; CNTY-308, a chimeric antigen receptor T-cell therapy targeting B-cell-mediated disorders; and CNTY-101, a natural killer cell therapy evaluated for autoimmune indications. It also designs additional programs for solid tumors and blood cancers. The company's therapies target patient populations living with serious metabolic, autoimmune, and oncologic illnesses.

The company operates an internal 53,000-square-foot cell therapy manufacturing facility located in Branchburg, New Jersey, which complies with European Union regulations. Its clinical trials and research collaborations involve institutions in Germany and the United States, while contract manufacturing support is located in Madison, Wisconsin. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Century Therapeutics's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of March 1, 2026, we had 78 full-time employees and 0 part-time employees.”